The University of Chicago Header Logo

Connection

George Bakris to Blood Pressure Monitoring, Ambulatory

Back to Details
This is a "connection" page, showing publications George Bakris has written about Blood Pressure Monitoring, Ambulatory.
George Bakris
Connection Strength
8.703
Blood Pressure Monitoring, Ambulatory
  1. Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control. J Am Coll Cardiol. 2021 03 16; 77(10):1300-1301.
    View in: PubMed
    Score: 0.762
  2. Ambulatory Blood Pressure Monitoring. JAMA. 2018 Nov 06; 320(17):1807-1808.
    View in: PubMed
    Score: 0.647
  3. Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit. J Am Coll Cardiol. 2016 Feb 02; 67(4):390-391.
    View in: PubMed
    Score: 0.534
  4. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7.
    View in: PubMed
    Score: 0.522
  5. Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. J Am Coll Cardiol. 2015 Mar 10; 65(9):959-60.
    View in: PubMed
    Score: 0.502
  6. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16; 64(11):1071-8.
    View in: PubMed
    Score: 0.475
  7. Role of ambulatory blood pressure monitoring in hypertension and diabetes. Curr Hypertens Rep. 2013 Jun; 15(3):137-42.
    View in: PubMed
    Score: 0.444
  8. Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease? J Hypertens. 2012 Mar; 30(3):466-7.
    View in: PubMed
    Score: 0.407
  9. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30.
    View in: PubMed
    Score: 0.369
  10. Assessing blood pressure control in dialysis patients: finally a step forward. Hypertension. 2009 Mar; 53(3):448-9.
    View in: PubMed
    Score: 0.328
  11. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20; 389(3):228-238.
    View in: PubMed
    Score: 0.224
  12. Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. Cardiol Clin. 2021 Aug; 39(3):377-387.
    View in: PubMed
    Score: 0.195
  13. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
    View in: PubMed
    Score: 0.176
  14. Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Curr Hypertens Rep. 2019 02 12; 21(2):12.
    View in: PubMed
    Score: 0.165
  15. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open. 2018 12 19; 8(12):e021038.
    View in: PubMed
    Score: 0.163
  16. Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension? Hypertension. 2018 10; 72(4):836-838.
    View in: PubMed
    Score: 0.161
  17. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84.
    View in: PubMed
    Score: 0.147
  18. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701.
    View in: PubMed
    Score: 0.146
  19. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54.
    View in: PubMed
    Score: 0.129
  20. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321.
    View in: PubMed
    Score: 0.126
  21. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013 May-Jun; 7(3):244-52.
    View in: PubMed
    Score: 0.109
  22. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10.
    View in: PubMed
    Score: 0.105
  23. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35.
    View in: PubMed
    Score: 0.103
  24. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012 May; 30(5):874-6.
    View in: PubMed
    Score: 0.103
  25. Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol. 2011 Dec 13; 9(2):75-7.
    View in: PubMed
    Score: 0.100
  26. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
    View in: PubMed
    Score: 0.099
  27. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72.
    View in: PubMed
    Score: 0.097
  28. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8.
    View in: PubMed
    Score: 0.094
  29. Pediatrics: Masked hypertension: a risk factor in children with CKD. Nat Rev Nephrol. 2010 Mar; 6(3):132-4.
    View in: PubMed
    Score: 0.089
  30. Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4.
    View in: PubMed
    Score: 0.087
  31. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8.
    View in: PubMed
    Score: 0.077
  32. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2.
    View in: PubMed
    Score: 0.068
  33. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 Jan; 151(1):176-84.
    View in: PubMed
    Score: 0.066
  34. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7.
    View in: PubMed
    Score: 0.065
  35. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005 Jun; 10(3):157-63.
    View in: PubMed
    Score: 0.064
  36. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.060
  37. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
    View in: PubMed
    Score: 0.058
  38. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 02 01; 41(2):295-302.
    View in: PubMed
    Score: 0.054
  39. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937.
    View in: PubMed
    Score: 0.053
  40. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens. 2022 10 01; 40(10):1847-1858.
    View in: PubMed
    Score: 0.052
  41. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
    View in: PubMed
    Score: 0.052
  42. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332.
    View in: PubMed
    Score: 0.051
  43. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2019 03 01; 34(3):515-523.
    View in: PubMed
    Score: 0.041
  44. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
    View in: PubMed
    Score: 0.039
  45. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
    View in: PubMed
    Score: 0.032
  46. Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306.
    View in: PubMed
    Score: 0.031
  47. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7.
    View in: PubMed
    Score: 0.029
  48. Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203.
    View in: PubMed
    Score: 0.028
  49. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
    View in: PubMed
    Score: 0.027
  50. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20.
    View in: PubMed
    Score: 0.024
  51. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.
    View in: PubMed
    Score: 0.023
  52. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010 Jul 01; 363(1):98.
    View in: PubMed
    Score: 0.023
  53. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604.
    View in: PubMed
    Score: 0.022
  54. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.
    View in: PubMed
    Score: 0.021
  55. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009 Apr; 27(4):673-9.
    View in: PubMed
    Score: 0.021
  56. Roundtable discussion: problems in the management of hypertension. J Clin Hypertens (Greenwich). 2002 May-Jun; 4(3):207-13.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.